A diary form quality of life questionnaire for Japanese patients with lung cancer and summarization techniques for longitudinal assessment

Respirology ◽  
1999 ◽  
Vol 4 (1) ◽  
pp. 53-61 ◽  
Author(s):  
Yoko Ishihara ◽  
Hiroshi Sakai ◽  
Naotaka Nukariya ◽  
Kunihiko Kobayashi ◽  
Shuichi Yoneda ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Japanese Patients ◽  
Life Questionnaire ◽  
Longitudinal Assessment ◽  
Quality Of Life Questionnaire ◽  
Form Quality

scholarly journals Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer

2020 ◽  
Vol 38 (3) ◽  
pp. 271-280 ◽  
Author(s):  
Julien Mazieres ◽  
Dariusz Kowalski ◽  
Alexander Luft ◽  
David Vicente ◽  
Ali Tafreshi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Combination Group ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Small Cell Lung ◽  
Quality Of Life Questionnaire ◽  
Related Quality ◽  
Health Related

PURPOSE In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel significantly improved overall survival, progression-free survival, and objective response rate in patients with previously untreated metastatic squamous non–small-cell lung cancer (NSCLC), with little impact on severe toxicity. We present patient-reported outcomes (PROs) from KEYNOTE-407. METHODS Patients were randomly assigned to receive 4 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus carboplatin plus paclitaxel or nab-paclitaxel, followed by pembrolizumab or placebo for an additional 31 cycles. Health-related quality of life (HRQoL) was evaluated using the European Organisation for Research and Treatment of Cancer Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and Quality of Life Questionnaire-Lung Cancer Module 13 (QLQ-LC13). Key PRO endpoints were change from baseline to weeks 9 and 18 (during and after platinum therapy) in the QLQ-C30 global health status/quality of life (GHS/QoL) score and time to deterioration in the composite endpoint of cough, chest pain, or dyspnea from the QLQ-C30 and QLQ-LC13. Two-sided, nominal P values are provided. RESULTS A total of 554 and 553 patients completed ≥ 1 QLQ-C30 or ≥ 1 QLQ-LC13 assessment, respectively. GHS/QoL score improved for the pembrolizumab-combination group (least squares [LS] mean [95% CI] change from baseline: week 9, 1.8 [−0.9 to 4.4]; week 18, 4.3 [1.7 to 6.9]) and deteriorated in the placebo-combination group (week 9, −1.8 [−4.4 to 0.7]; week 18, −0.57 [−3.3 to 2.2]). Between-group differences were improved for the pembrolizumab-combination group (difference in LS mean scores: week 9, 3.6 [95% CI, 0.3 to 6.9], nominal P = .0337; week 18, 4.9 [1.4 to 8.3], nominal P = .0060). Median time to deterioration in cough, chest pain, or dyspnea was not reached in either group (hazard ratio, 0.79; 95% CI, 0.58 to 1.06]; nominal P = .125). CONCLUSION Addition of pembrolizumab to chemotherapy maintained or improved HRQoL measurements relative to baseline and improved HRQoL versus chemotherapy alone at weeks 9 and 18. These results support use of pembrolizumab plus chemotherapy as first-line therapy for metastatic squamous NSCLC.

scholarly journals Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development

Cancer ◽  
2015 ◽  
Vol 121 (24) ◽  
pp. 4300-4323 ◽  
Author(s):  
Michael Koller ◽  
Sophie Warncke ◽  
Marianne J. Hjermstad ◽  
Juan Arraras ◽  
Cecilia Pompili ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Systematic Review ◽  
Clinical Trials ◽  
Life Questionnaire ◽  
Review Of The Literature ◽  
Quality Of Life Questionnaire ◽  
Eortc Qlq

scholarly journals Translation and cultural adaptation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer Module for quality of life assessment in patients with lung cancer in Brazil

2019 ◽  
Vol 45 (4) ◽  
Author(s):  
Ana Paula Ramos Marinho ◽  
Gracielle Fin ◽  
Antuani Rafael Baptistella ◽  
Rudy José Nodari Júnior ◽  
Magnus Benetti
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cultural Adaptation ◽  
Life Questionnaire ◽  
Pilot Testing ◽  
Language Version ◽  
Quality Of Life Questionnaire ◽  
European Organisation ◽  
Cancer Module

ABSTRACT Objective: To translate the European Organisation for Research and Treatment of Cancer (EORTC) 29-item Quality of Life Questionnaire-Lung Cancer Module (QLQ-LC29, developed for the assessment of quality of life in patients with lung cancer) to Portuguese, conducting a pilot study of the Portuguese-language version and adapting it for use in Brazil. Methods: For the translation, cultural adaptation, and pilot testing of the QLQ-LC29, we followed the guidelines established by the EORTC. The translation (English → Portuguese) and back-translation (Portuguese → English) were both carried out by translators, working independently, who were native speakers of one language and fluent in the other. After review, a draft version was created for pilot testing in lung cancer patients in Brazil. Results: A total of 15 patients diagnosed with lung cancer completed the Portuguese-language version of the questionnaire. At the end of the process, we conducted a structured interview to identify any patient difficulty in understanding any of the questions. The final versions were sent to the EORTC and were approved. Conclusions: The Portuguese-language version of the EORTC QLQ-LC29 appears to be a useful, important, reliable questionnaire that is a valid tool for assessing quality of life in patients with lung cancer in Brazil.

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

2004 ◽  
Vol 22 (16) ◽  
pp. 3238-3247 ◽  
Author(s):  
Román Pérez-Soler ◽  
Abraham Chachoua ◽  
Lisa A. Hammond ◽  
Eric K. Rowinsky ◽  
Mark Huberman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Tumor Response ◽  
Objective Response ◽  
Symptom Improvement ◽  
Life Questionnaire ◽  
Small Cell Lung ◽  
Quality Of Life Questionnaire ◽  
Cutaneous Rash

Purpose Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR-expressing non–small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement. Patients and Methods Fifty-seven patients received an oral, continuous daily dose of 150 mg of erlotinib. Assessments of objective response used WHO and Response Evaluation Criteria in Solid Tumors criteria. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, supplemented with a lung cancer module, Quality of Life Questionnaire LC13, was used to measure health-related quality of life. Additional analyses were performed to identify predictors of response and survival. Results The objective response rate was 12.3% (95% CI, 5.1% to 23.7%). Responses were observed regardless of type or number of prior chemotherapy regimens. Median survival time was 8.4 months (95% CI, 4.8 to 13.9 months), and the 1-year survival rate was 40% (95% CI, 28% to 54%). Erlotinib therapy was associated with tumor-related symptom improvement. The drug was well tolerated; drug-related cutaneous rash and diarrhea were observed in 75% and 56% of patients, respectively. One patient experienced toxicity consisting of severe grade 3 rash and diarrhea. Time since diagnosis and good performance status were significant predictors of survival in a multivariate Cox proportional hazards model, whereas HER1/EGFR staining intensity was not. Additionally, survival correlated with the occurrence and severity of rash. Conclusion Erlotinib was active and well tolerated in this patient population, and further clinical development is clearly warranted. Cutaneous rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies.

Sign in / Sign up

Export Citation Format

Share Document